Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 黑料网 Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Advances in human genome analysis, OMICS science and big data analysis continue to make inroads for molecular
pathology to assist in personalized medicine. Through proper analytical and clinical validation, many of those newly
discovered biomarkers such as SNPs/SNVs and INDELs that are associated with specific diseases or responses to various
drug therapies, could be used to develop new molecular diagnostic tests for prediction, diagnosis, treatment and monitoring
of various diseases. Since these molecular-based testing can be used to assess individual�??s genetic variability and probability
for onset of certain diseases or responses to various drug therapies, customized treatment plan or therapies could be designed
specifically for each individual patient. As more and more medical professionals realize the benefits of being able to use these
useful molecular pathology tools for precision medicine, personalized patient care through individualized molecular pathology
testing is no longer a future perspective but rather a reality in many of the major medical centers in the United States including
the University of Maryland School of Medicine and Medical Center. There is no doubt that individualized molecular testing
will soon become a routine clinical practice for personalized patient care world-wide. However, successful transition of such
a paradigm shift from traditional medicine to personalized medicine requires integrated and concerted effort from all allied
medical professionals. Education and continued education of healthcare administrators, physicians, medical practitioners and
laboratory personnel on the pharmacogenomics testing and associated patient care are among the essential steps for successful
transition and implementation of personalized medicine. This lecture will introduce some of the key factors associated with
this paradigm shift from current medicine to personalized medicine, review different categories of pharmacogenomics testing
that are designed for personalized healthcare. Specific case reports will be presented drawn from our own experiences on how
individualized molecular testing has helped us in our clinical practice and personalized patient care. Future perspectives on
this exciting new area of molecular pathology and medicine will also be discussed.
Biography
Richard Y Zhao, a Molecular Pathologist, is a Tenured Professor of Pathology, Microbiology-Immunology and Human Virology at the University of Maryland School
Of Medicine. He is also the Division Head of Molecular Pathology in the Department of Pathology, Director of Translational Genomics Laboratory in the School of
Medicine, and Director of Molecular Diagnostics Laboratory at the University of Maryland Medical Center. He has published over one hundred scientific papers
and has served on numerous scientific editorial boards including Clinical and Applied Immunology Reviews, Clinical Laboratory Science, Cell Research, Cell and
Biosciences, Chinese Journal of Clinical and Experimental Virology, Journal of Clinical and Experimental Pathology, Frontiers in Virology, Microbial Cell, PLoS One
and Retrovirology. He has been invited to review scientific grant applications for funding agencies of over 10 different countries and has chaired a number of NIH
grant review study panels. He has been invited to give scientific and clinical lectures world-wide.
Relevant Topics
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, 黑料网 Journals
